• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 11:03:23 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $IQV alert in real time by email
    SC 13G/A 1 tv01166-iqviaholdingsinc.htm SCHEDULE 13G/A iqviaholdingsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 7)*

    Name of issuer:  IQVIA Holdings Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  46266C105

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  46266C105

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    316,862

    7.  SOLE DISPOSITIVE POWER

    20,115,435

    8.  SHARED DISPOSITIVE POWER

    839,252

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    20,954,687

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.93%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    IQVIA Holdings Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    4820 Emperor Blvd.
    Durham, North Carolina 27703

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    46266C105

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    20,954,687

      (b) Percent of Class:

    10.93%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  316,862

    (iii)  sole power to dispose of or to direct the disposition of:  20,115,435

    (iv)  shared power to dispose or to direct the disposition of:  839,252

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $IQV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IQV

    DatePrice TargetRatingAnalyst
    12/2/2025$265.00Overweight
    Morgan Stanley
    11/13/2025$260.00Outperform
    BMO Capital Markets
    11/3/2025$215.00Buy → Hold
    TD Cowen
    10/29/2025$258.00Neutral → Outperform
    Robert W. Baird
    10/9/2025$235.00Hold → Buy
    HSBC Securities
    9/9/2025$225.00Hold → Buy
    Jefferies
    4/25/2025$160.00Buy → Hold
    HSBC Securities
    4/10/2025$170.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $IQV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Fedock Michael J. covered exercise/tax liability with 381 shares, decreasing direct ownership by 7% to 5,391 units (SEC Form 4)

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    1/30/26 5:04:36 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    New insider Haas Bernd claimed ownership of 16,589 shares (SEC Form 3)

    3 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    1/9/26 6:01:56 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    New insider Grenfell Alistair claimed ownership of 17,874 shares (SEC Form 3)

    3 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    1/9/26 6:00:31 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on IQVIA with a new price target

    Morgan Stanley resumed coverage of IQVIA with a rating of Overweight and set a new price target of $265.00

    12/2/25 8:26:39 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    BMO Capital Markets initiated coverage on IQVIA with a new price target

    BMO Capital Markets initiated coverage of IQVIA with a rating of Outperform and set a new price target of $260.00

    11/13/25 9:14:20 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA downgraded by TD Cowen with a new price target

    TD Cowen downgraded IQVIA from Buy to Hold and set a new price target of $215.00

    11/3/25 9:08:28 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    SEC Filings

    View All

    SEC Form 144 filed by IQVIA Holdings Inc.

    144 - IQVIA HOLDINGS INC. (0001478242) (Subject)

    12/18/25 5:41:10 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

    12/9/25 4:55:11 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 8-K filed by IQVIA Holdings Inc.

    8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

    11/5/25 4:29:39 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Danhakl John G bought $255,740 worth of shares (1,275 units at $200.58) (SEC Form 4)

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    2/7/25 7:03:59 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration

    IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced a strategic long-term collaboration with Boehringer Ingelheim. Boehringer Ingelheim has selected IQVIA's Data-as-a-Service (DaaS+) technology offering as the accelerator to power its global commercial data harmonization and transformation journey. This collaboration will enable Boehringer Ingelheim to scale its commercial data products and analytics ambitions across therapeutic areas and regional teams, leveraging an industry-leading global data model. "We are excited about the possibilities of working

    1/29/26 8:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Named to the Fortune® World's Most Admired Companies™ List, Ranked No. 1 in Its Sector for Fifth Consecutive Year

    IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2026 Fortune® World's Most Admired Companies™ list. This is the fifth year in a row IQVIA has earned first place in the Health Care: Pharmacy and Other Services category, and the ninth consecutive year it has appeared on the list. Notably, IQVIA earned first place in its category on seven of the nine key attributes evaluated — innovation, people management, use of corporate assets, financial soundness, long-term investment value, quality of products/services and global competitiveness. "This recognition reflects the unwavering

    1/22/26 4:05:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 5, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at: http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join via the IQVIA Investor Relations website at: http:/

    1/20/26 4:45:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Financials

    Live finance-specific insights

    View All

    IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 5, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at: http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join via the IQVIA Investor Relations website at: http:/

    1/20/26 4:45:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Reports Third-Quarter 2025 Results

    Revenue of $4,100 million, up 5.2 percent year-over-year GAAP Net Income of $331 million, Adjusted EBITDA of $949 million GAAP Diluted Earnings per Share of $1.93, Adjusted Diluted Earnings per Share of $3.00 R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.15x R&D Solutions contracted backlog of $32.4 billion, up 4.1 percent year-over-year Operating Cash Flow of $908 million; Free Cash Flow of $772 million, up 35 percent year-over-year, representing 150 percent of Adjusted Net Income IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to

    10/28/25 7:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-quarter 2025 financial results before the market opens on Tuesday, October 28, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com.

    9/30/25 4:15:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Leadership Updates

    Live Leadership Updates

    View All

    IQVIA Appoints Richard Staub III President of Research & Development Solutions

    IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec

    9/25/23 8:01:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions

    IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all

    6/7/22 8:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati

    3/14/22 9:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IQVIA Holdings Inc.

    SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

    8/15/24 7:57:23 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by IQVIA Holdings Inc.

    SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

    2/14/24 4:11:54 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by IQVIA Holdings Inc. (Amendment)

    SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

    1/25/24 4:59:33 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care